KRAS and neoplasm: All BRAF and KRAS mutations identified in the exome sequencing data of the polyps were confirmed by targeted molecular analysis which demonstrates the ability of our approach to identify relevant variants with a fraction of variant reads 3 5% in tumour DNA.